← Back to Search

Convulsive Therapy

Convulsive Therapies for Bipolar Disorder (CORRECT-BD Trial)

Q: Is the research team currently seeking participants for this investigation?

<p>Affirmative. According to details on clinicaltrials.gov, this medical trial is currently enrolling participants and was last updated August 5th 2021 after being first posted September 21st 2018. One hundred individuals are needed for the study at 3 distinct sites of research.</p>

Q: How many participants are enrolled in the experiment at its peak capacity?

<p>Affirmative. Clinicaltrials.gov has records that this trial, posted on September 21st 2018 and last updated August 5th 2021, is actively recruiting candidates to join the experiment with 100 participants across 3 sites being sought out for inclusion.</p>

N/A

Waitlist Available

Led By Daniel Blumberger, MD, MSc

Research Sponsored by Centre for Addiction and Mental Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must be voluntary and competent to consent to treatment and research procedures according to ECT/MST attending psychiatrist

Patients must be 18 years of age or older

Timeline

Screening 3 weeks

Treatment Varies

Follow Up greater than 8 treatments (2.5 weeks)

Awards & highlights

CORRECT-BD Trial Summary

This trial is testing whether magnetic seizure therapy is more effective and tolerable than electroconvulsive therapy for treating bipolar disorder.

Who is the study for?

This trial is for adults over 18 with non-psychotic Bipolar Disorder (Type I or II) who have a significant level of depression. They must be able to consent, follow the treatment schedule, and keep their current antidepressant constant. Exclusions include major unstable illnesses, pregnancy intention during the study, primary psychotic disorders, recent substance abuse, certain neurological conditions or implants, high doses of benzodiazepines or anticonvulsants.Check my eligibility

What is being tested?

The trial compares Magnetic Seizure Therapy (MST) with Electroconvulsive Therapy (ECT) in treating bipolar depression. It aims to find out if MST can be an effective alternative to ECT by providing better response rates in patients resistant to other treatments.See study design

What are the potential side effects?

While not explicitly listed here, side effects may include memory issues and confusion typically associated with ECT. MST might present similar risks due to its nature as a convulsive therapy but is being studied for potentially fewer cognitive side effects.

CORRECT-BD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am willing and able to agree to treatment and research procedures.

Select...

I am 18 years old or older.

CORRECT-BD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ greater than 8 treatments (2.5 weeks)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~greater than 8 treatments (2.5 weeks)

This trial's timeline: 3 weeks for screening, Varies for treatment, and greater than 8 treatments (2.5 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cognitive adverse effects as indexed by the Autobiographical Memory Test (AMT)

Remission (score </= 10) on the Hamilton Rating Scale for Depression - 24 (HRSD-24)

Secondary outcome measures

Improvement in symptom severity of Suicidal Ideation as measured by the Scale for Suicidal Ideation (SSI)

Number of self-reported and clinical-reported adverse events

CORRECT-BD Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Magnetic Seizure Therapy (MST)Experimental Treatment1 Intervention

MST treatments will be administered using the MagPro MST with Cool TwinCoil.

Group II: Electroconvulsive Therapy (ECT)Active Control1 Intervention

ECT treatments will be administered using the MECTA spECTrum 5000Q or MECTA Sigma

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Centre for Addiction and Mental HealthLead Sponsor

355 Previous Clinical Trials

81,144 Total Patients Enrolled

University of British ColumbiaOTHER

1,415 Previous Clinical Trials

2,466,916 Total Patients Enrolled

Brain CanadaOTHER

17 Previous Clinical Trials

5,864 Total Patients Enrolled

Media Library

ECT (Convulsive Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT03641300 — N/A

Depression, Bipolar Disorder Research Study Groups: Electroconvulsive Therapy (ECT), Magnetic Seizure Therapy (MST)

Depression, Bipolar Disorder Clinical Trial 2023: ECT Highlights & Side Effects. Trial Name: NCT03641300 — N/A

ECT (Convulsive Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03641300 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the research team currently seeking participants for this investigation?

"Affirmative. According to details on clinicaltrials.gov, this medical trial is currently enrolling participants and was last updated August 5th 2021 after being first posted September 21st 2018. One hundred individuals are needed for the study at 3 distinct sites of research."

Answered by AI

How many participants are enrolled in the experiment at its peak capacity?

"Affirmative. Clinicaltrials.gov has records that this trial, posted on September 21st 2018 and last updated August 5th 2021, is actively recruiting candidates to join the experiment with 100 participants across 3 sites being sought out for inclusion."

Answered by AI